Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Person › Details

Martin Heidecker (Boehringer Ingelheim Venture Fund (BIVF))

Heidecker, Martin (Boehringer 201201 Director at Boehringer Ingelheim Venture Fund)

 

Organisation Organisation Boehringer Ingelheim Venture Fund (BIVF)
Products Product venture capital
  Product 2 pharmaceutical
     

AMP-Therapeutics GmbH. (1/5/12). "Press Release: AMP Therapeutics Completes A Round Financing". Leipzig.

AMP Therapeutics GmbH, a spin-off company of the University of Leipzig developing novel antibiotic therapies, announced today the completion of a Series A equity fund financing. Investors in the round were Boehringer Ingelheim Venture Fund and Novartis Venture Funds.

Proceeds from the financing will be used to advance AMPT's Gram-negative antibiotic program and enhance AMPT's R&D. In particular, the financing will accelerate the development of AMPT'S product pipeline, including lead compounds developed from insect peptides.

"We believe this Series A investment validates the premise of AMPT's innovative and unique approach to developing a new class of drugs to treat serious bacterial infections," said Knut Adermann, Managing Director responsible for Research and Development. Marc W. Hentz, Managing Director responsible for Finances and Business Development further commented: "We have succeeded in attracting renowned, science-driven investors who share our belief in AMPT's lean concept towards translation of novel antibiotic agents into the market. This financing enables us to address the global health threat of growing bacterial resistance to antibiotics with our novel approach to combating Gram-negative pathogens.

AMPT has made several board appointments to reflect its new shareholder mix; Drs. Martin Heidecker and Henry Skinner have been named directors. They join existing board members Dr. Bernd Eisele, CEO of VPM Vakzine Projekt Management GmbH and AMP Therapeutics co-founder Prof. Dr. Jörg Gabert.

"We believe that AMPT's antibiotic therapies have significant potential to address serious Gram-negative infections caused by multi-drug resistant bacteria" said Henry Skinner, Ph.D., Managing Director, Novartis Venture Funds.

Dr. Martin Heidecker, Director at Boehringer Ingelheim Venture Fund, commented, "We are pleased to join this project and look forward to working with the company as it continues to test and develop its lead compounds."


About AMP Therapeutics (AMPT)

AMP Therapeutics was founded in 2009 as a spin-off from Prof. Ralf Hoffmann's laboratory at the University of Leipzig and is based in the Center for Biotechnology and Biomedicine at BIO CITY in Leipzig, Germany. AMPT is engaged in the discovery and commercialization of new medicines for the treatment of severe bacterial infections predominantly caused by drug-resistant Gram-negative bacteria. Infections caused by drug-resistant pneumonia, bloodstream infections, surgical site infections and urinary tract infections represent a major global health threat with an unfavorable prognosis and are largely untreatable with existing antibiotics. AMPT addresses this significant unmet medical need by advancing the preclinical and clinical development of its proprietary antibacterial compounds. AMPT's technology is based on naturally occurring antimicrobial peptides found across various species.
www.amp-therapeutics.com


About the Boehringer Ingelheim Venture Fund (BIVF)

The BIVF was formed in March 2010 and invests in biotechnology and start-up companies that provide ground-breaking therapeutic approaches and medicinal technologies to help drive innovation in medical science. These may include - but are not limited to - novel technologies to address so far undrugable targets, new- generation vaccines and new biological entities, such as antibody-dependent oncolysis. Novel therapeutic targets and disease-related biomarkers, as well as new approaches in regenerative medicine, are an additional focus.
www.boehringer-ingelheim-venture.com


About the Novartis Venture Funds (NVF)

NVF currently manages over $750 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that are critical to patient care. NVF primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems. NVF invests for financial objectives at all stages, but prefers to invest in the early-stages of company development. With eight investment professionals, located in Basel, Switzerland and Cambridge, MA, the team has extensive experience in pharmaceutical R&D and venture capital.
www.venturefund.novartis.com


Contact: Dr. Marc W. Hentz, Managing Director AMP-Therapeutics GmbH
info@amp-therapeutics.com

   
Record changed: 2020-10-19

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px


More documents for Martin Heidecker


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81




» top